INCY Incyte Corporation
Company Analysis
Latest News
🔴 Incyte is trading 27.09% down in after-hours trading with no clear catalyst identified
Incyte is trading 27.09% down at $92.54 after falling sharply from its September 22 regular-session close of $126.93; no clear company-specific catalyst has...
🔴 Incyte is trading 22% down in pre-market with no clear company-specific catalyst identified
Incyte is trading 21.63% down now at $97.69 after no clear company-specific catalyst was identified in available September 22, 2026 coverage. - Recent...
Incyte Jumps 6% on Canadian Reimbursement Win — But Can a Single Province Move the Needle on a $5 Billion Revenue Machine?
Shares of Incyte surged 6.2% to $129.00 after Ontario became the first Canadian province to publicly fund its cancer drug tafasitamab for patients with...
🟢 Incyte is trading 6.2% up in pre-market after Ontario announced accelerated public funding for MINJUVI
Incyte is trading $129.00 (+6.20%) in pre-market after Ontario announced accelerated public funding for MINJUVI in relapsed or refractory follicular...
Incyte Secures Early Ontario Funding for MINJUVI, Accelerating Patient Access
Incyte’s MINJUVI (tafasitamab) will receive funding in Ontario through the province’s Funding Accelerated for Specific Treatments (FAST) Program. This...
🟢 Incyte is trading 4.09% up in after-hours trading amid broadly positive U.S. equity sentiment
Incyte is trading at $134.10, +4.09% in after-hours trading amid broadly positive U.S. equity sentiment. - This follows September 2, 2026’s regular-session...
Incyte Enters Pricing Agreement with CMS for Jakafi in State Medicaid Programs
Incyte Corporation has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (CMS) to align the pricing of its drugs Jakafi and...
Incyte Secures $337 Million from Major Funds, Citing Positive Cancer Data
Incyte Corporation attracted significant institutional investment according to filings released on August 27, 2026. These second-quarter transactions reflect...
🟢 Incyte rises 4.0% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Incyte is trading 4.2% down today on profit-taking after post-earnings surge
Incyte is trading 4.2% down at $121.81 as the stock undergoes a period of normalization and profit-taking following a sharp two-day rally. • The stock...
🔴 Incyte is trading 7.6% down today following its Q2 earnings release and guidance update
Incyte is trading at $120.00, down 7.6% in after-hours trading following its second-quarter 2026 earnings release and updated guidance. • While revenue and...
Incyte Crushes Q2 Estimates on a $246 Million Accounting Windfall — But Can Investors Count on This Growth Rate Sticking?
Shares surged +10.6% to $131.46 after Incyte delivered a second quarter that blew past Wall Street on almost every metric. But the headline numbers carry a...
🟢 Incyte is trading 10.59% up today on Q2 earnings beat and raised guidance
Incyte is trading at $131.46 (+10.59%) after second-quarter results beat estimates and management raised full-year guidance. • The company reported $1.67...
🟢 Incyte is trading 4.6% up today after a strong Q2 earnings beat and raised guidance
Incyte is trading 4.6% up today at $125.32 after reporting a strong second-quarter earnings beat and raising its full-year guidance. • The rally is primarily...
Incyte's second quarter revenue and EPS significantly beat estimates, driven by a one-time Opzelura benefit, leading to raised full-year guidance.
Incyte reported second quarter 2026 revenue of $1.67 billion, up 38% year-over-year, and non-GAAP diluted EPS of $3.09. These results significantly surpassed...
Incyte Corporation Q2 2026 Earnings Preview: What Analysts Expect on July 28, 2026
For the second quarter of 2026, analysts anticipate Incyte to report consensus revenue of $1.40 billion and an adjusted EPS of $1.61, while the stock currently...
Incyte and Halozyme Announce Collaboration for Subcutaneous Cancer Drug Formulation
Incyte Corporation and Halozyme Therapeutics formed a global collaboration and license agreement. They will develop a subcutaneous formulation for Incyte's...
Incyte's Latarcibart Shows 81% Reduction in Bleeding Rate in Phase 1/2 VWD Study
Incyte announced positive results from its Phase 1/2 study of latarcibart for Von Willebrand Disease (VWD). The company presented this data at the ISTH 2026...
Incyte completes acquisition of Vega Therapeutics for $1.25B upfront payment
Incyte Corporation has completed its previously announced acquisition of Vega Therapeutics, Inc., a subsidiary of Star Therapeutics, to expand its hematology...
Incyte's Opzelura wins EU backing, set to be first steroid-free JAK inhibitor
Incyte announced on June 26, 2026, that its Opzelura (ruxolitinib) cream received a positive CHMP opinion. The committee recommended the drug for adults with...